Skip to main content

Advertisement

Fig. 5 | Clinical and Molecular Allergy

Fig. 5

From: Non-digestible oligosaccharides scFOS/lcFOS facilitate safe subcutaneous immunotherapy for peanut allergy

Fig. 5

PE specific antibody levels in serum. ac Allergen-specific IgE, IgG1 and IgG2a measured by ELISA in serum of mice from treatment protocol 2 (Fig. 1). Data are represented as mean ± SEM n = 6–8 mice/group. Statistical analysis was performed, after log transformation, using a one-way ANOVA and Bonferroni’s post hoc test (on each day). All treatment groups were compared to the PE-sensitized control group and significant differences were indicated with letters: a P < 0.05; aa P < 0.01; aaa P < 0.001; aaaa P < 0.0001. Letters used: s for PBS-sensitized control group; a for scFOS/lcFOS control group; b for SCIT; c for SCIT plus scFOS/lcFOS. s.c., subcutaneous; i.g. intra gastric; i.p., intraperitoneal challenge; PE, peanut extract; FF, scFOS/lcFOS; IT, immunotherapy

Back to article page